| Pathway
|
Gap Junction Assembly
|
|
Prostate Cancer Overview
|
|
Metastatic Colorectal Cancer Overview
|
|
Dystrophin Glycoprotein Complex Signaling in Duchenne Muscular Dystrophy
|
|
Ca2+ Overload in Duchenne Muscular Dystrophy
|
|
Osteoclast Activation in Multiple Myeloma
|
|
T-cell Acute Lymphoblastic Leukemia Overview
|
|
B-cell Chronic Lymphocytic Leukemia Overview
|
|
Hodgkin Lymphoma Overview
|
|
Diffuse Large-B-cell Lymphoma, ABC Subtype
|
|
Diffuse Large-B-cell Lymphoma Overview
|
|
Mantle Cell Lymphoma Overview
|
|
PI3K/AKT/MTOR, NF-kB and BCR Signaling Deregulation in Mantle Cell Lymphoma
|
|
Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Overview
|
|
Splenic Marginal Zone Lymphoma Overview
|
|
Effect of NO on Vasodilation and Triptans on Vasoconstriction in Familial Hemiplegic Migraine
|
|
Proliferative Diabetic Retinopathy
|
|
Obesity Induced Insulin Resistance in Myocytes
|
|
Insulin Resistance in Hepatocytes
|
|
Adipose Tissue Inflammation Provokes Insulin Resistance
|
|
Role of Protein Kinase C in Diabetic Microangiopathy
|
|
Impaired Peripheral Tolerance to Autoantigens in Diabetes Mellitus Type 1
|
|
Insulin Influence on Lipogenesis
|
|
Peripheral Tissue Microangiopathy in Insulin Resistance
|
|
Congenital Secondary (Central) Hypothyroidism
|
|
Congenital Hypothyroidism Due to Thyroid-Stimulating Hormone Resistance
|
|
Thyroid Dysfunction in Graves Disease
|
|
Cardiovascular Effects of Hyperthyroidism
|
|
Common Non-genomic Effects of Thyroid Hormones
|
|
Effects of Hyperthyroidism on Bone Remodeling
|
|
Primary Overt Hypothyroidism Overview
|
|
Overt Hypothyroidism Influence on Thyroid-Stimulating Hormone Secretion
|
|
Central Hypothyroidism Overview
|
|
Tertiary Hypothyroidism Overview
|
|
Deregulation of Cell Cycle in Melanoma
|
|
Block of Apoptosis in Melanoma
|
|
MITF as a Regulator of Melanoma Cell Development
|
|
WNT Signaling in Melanoma
|
|
Melanoma Overview
|
|
Defective Clearance of Apoptotic Keratinocytes in Systemic Lupus Erythematosus
|
|
Th2 Cell Function in Systemic Lupus Erythematosus
|
|
B-cell Activation in Systemic Lupus Erythematosus
|
|
Th0 Cell Aberrant Activation in Systemic Lupus Erythematosus
|
|
Th17 Cell Function in Systemic Lupus Erythematosus
|
|
T-cell-Dependent B-cell Activation
|
|
T-cell-Independent B-cell Activation
|
|
Natural Killer Cell Activation through C-type Lectin-like Receptors
|
|
Natural Killer Cell Activation through ITSM-Containing Receptors
|
|
Natural Killer Cell Activation through ITAM-Containing Receptors
|
|
V(D)J Recombination Activation
|
|
Peripheral T-cell Tolerance Overview
|
|
CD8+ T-cell Activation
|
|
Natural Killer Cell Activation
|
|
Th17 Cell Differentiation
|
|
Th1 Cell Differentiation
|
|
T-cell Receptor Signaling
|
|
Regulatory T-cell Differentiation
|
|
Th2 Cell Differentiation
|
|
Cancer Overview
|
|
Necrosis of Neurons Caused by Energy Deficiency in Late Vasospasm
|
|
NO Synthesis in Early Vasospasm
|
|
Contraction due Vasospasm
|
|
CFTR-Related Ion-Channel Dysfunction in Cystic Fibrosis Airway Epithelium (Class III Mutations)
|
|
CFTR Up-regulates the Oxidative Stress in Airway Epithelium in Cystic Fibrosis
|
|
CFTR Expression in Epithelial Cells (Class I Mutations)
|
|
Airway Epithelial Cell Dysfunction in Cystic Fibrosis (Overview)
|
|
Activation and Proliferation of Th1 Cells in Atherosclerosis
|
|
Onset of Atopic Dermatitis
|
|
Mast Cells in Atopic Dermatitis
|
|
Mechanisms of Cardiomyocyte Hypertrophy in Hypertrophic Cardiomyopathy
|
|
Hypertrophic Cardiomyopathy Overview
|
|
Smooth Muscle Cell Dysfunction in Pulmonary Arterial Hypertension
|
|
Primary Glioblastoma
|
|
Secondary Glioblastoma
|
|
Astrocytoma
|
|
CCR5 Signaling in Macrophages in HIV Type 1 Infection
|
|
Block of CD4+ T-cell Signaling in HIV Type 1 Infection
|
|
CD4+ T-cell Death in HIV Type 1 Infection
|
|
Ca2+ Toxicity in Lens Cells
|
|
Diabetes-Induced Cataract
|
|
Impairment of EDN, NRG, NRTN, and GDNF/RET Signaling in Hirschsprung Disease
|
|
FSH Action in Polycystic Ovary Syndrome
|
|
Impaired Steroidogenesis in Polycystic Ovary Syndrome
|
|
Block of Ovulation in Polycystic Ovary Syndrome
|
|
PTPN22 Involvement in Rheumatoid Arthritis
|
|
Induction of Apoptosis and Immediate Early Gene Activation in Hippocampal Neurons Following Seizures
|
|
Effects of BDNF Upregulation Induced by Seizures
|
|
Cold Stress and Adrenoceptor Alpha 2C Signaling in Raynaud Disease
|
|
Regulation of Vascular Reactivity in Raynaud Disease
|
|
Mechanism of Skin Fibrosis in Systemic Scleroderma
|
|
B-cells Function in Systemic Scleroderma
|
|
Role of Th2 cells in Systemic Scleroderma
|
|
Myocardial Remodeling in Myocardial Ischemia
|
|
WHIM Syndrom Overview
|
|
Glycosylphosphatidylinositol(GPI)-anchor biosynthesis
|
|
Metabolism of triacylglycerols
|
|
Metabolism of glycerophospholipids and ether lipids
|
|
Inositol phosphate metabolism
|
|
ADORA3 -> mast cell degranulation
|
|
ADRA1 -> vasoconstriction
|
|
ADRA2C/ADRB2 -> vasoconstriction
|
|
ADRA1 -> prostaglandin generation
|
|
ADRA1A -> IL6 production
|
|
ADRA1 -> ion channels
|
|
ADRA2C/ADRB2 -> synaptic endocytosis
|
|
GRM1/5 (postsynaptic) -> ion channels
|
|
P2RY11/13/14 -> IL8/10 production
|
|
BDKRB1/2 -> prostaglandin generation
|
|
BDKRB1/2 -> ion channels
|
|
PTGER1/4 -> vascular motility
|
|
PTGER2/3 -> vascular motility
|
|
PTGFR -> vasoconstriction
|
|
PTGER2/3 -> inflammation-related expression targets
|
|
PTGIR -> IL6 production
|
|
HTR1 -> vascular motility
|
|
HTR5 -> TNF production
|
|
HTR1 -> IL6 production
|
|
HTR2 -> membrane transport
|
|
HTR1 -> membrane transport
|
|
CNR1/2 -> membrane transport
|
|
CNR1/2 -> IL1B/2/4/6/10 production
|
|
DRD2/4 -> membrane transport
|
|
DRD3 -> dopamine uptake
|
|
Nociception-related DRD2 expression targets
|
|
EDNRA/B -> vascular motility
|
|
CHRM1/2/3/5 -> ion channels
|
|
CHRM1/2/3 -> vascular motility
|
|
CHRM1 -> IL2 production
|
|
TACR1 -> membrane transport
|
|
NPY1R -> CRH/POMC production
|
|
CCKBR -> neurotransmitter uptake
|
|
Nociception-related NTSR1 expression targets
|
|
TAAR1 -> neurotransmitter uptake
|
|
NTRK1/2/3 -> acetylcholine production
|
|
GALR1/2/3 -> neurotransmitter metabolism
|
|
GALR1/2/3 -> POMC/NPY production
|
|
GFs/TNF -> ion channels
|
|
Regulation of potassium flux
|
|
Summarized nociception-related expression targets
|
|
Summarized vascular motility pathway
|
|
Regulation of calcium flux
|
|
OPRK -> pain perception
|
|
FGFR -> AP-1/CREB/CREBBP/ELK-SRF/MYC signaling
|
|
PDGFR -> AP-1/MYC signaling
|
|
VEGFR -> AP-1/CREB/MYC signaling
|
|
HGFR -> AP-1/CREB/MYC signaling
|
|
AngiopoietinR -> AP-1 signaling
|
|
ErythropoietinR -> AP-1/CREB/MYC signaling
|
|
ThrombopoietinR -> AP-1/CREB/ELK-SRF/MYC signaling
|
|
EGFR -> AP-1/CREB/ELK-SRF/MYC signaling
|
|
EGFR -> NCOR2 signaling
|
|
PTPRC -> BCL6 signaling
|
|
T-cell receptor -> ATF/CREB signaling
|
|
T-cell receptor -> AP-1 signaling
|
|
T-cell receptor -> NF-kB signaling
|
|
FcIgER -> ELK-SRF signaling
|
|
EGFR/ERBB2 -> HIF1A signaling
|
|
EGFR -> AP-1/ATF2 signaling
|
|
EGFR/ERBB2 -> TP53 signaling
|
|
EGFR/ERBB3 -> MEF/MYOD/NFATC/MYOG signaling
|
|
ERBB2/3 -> EP300/ETS/ETV/SP1 signaling
|
|
EGFR -> SMAD1 signaling
|
|
FGFR -> RUNX2 signaling
|
|
KIT -> MITF signaling
|
|
VEGFR -> NFATC signaling
|
|
VEGFR -> ATF/CREB/ELK-SRF signaling
|
|
GDNF -> HSF1 signaling
|
|
NTRK -> AP-1/CREB/ELK-SRF/MYC/SMAD3/TP53 signaling
|
|
UrokinaseR -> ELK-SRF signaling
|
|
ICAM1 -> AP-1/CREB/ELK-SRF signaling
|
|
FibronectinR -> AP-1/ELK-SRF/SREBF signaling
|
|
SELE -> ELK-SRF signaling
|
|
B-cell receptor -> AP-1 signaling
|
|
CD19 -> AP-1/ELK-SRF signaling
|
|
B-cell receptor -> NF-kB signaling
|
|
ErythropoietinR -> ELK-SRF/FOS signaling
|
|
EDG2 -> ELK-SRF signaling
|
|
CholinergicRm -> CREB/ELK-SRF signaling
|
|
CannabinoidR -> AP-1/EGR signaling
|
|
NeuropeptideYR -> ATF/CREB signaling
|
|
DopamineR2 -> AP-1/CREB/ELK-SRF signaling
|
|
SerotoninR1 -> FOS signaling
|
|
PTAFR -> AP-1/ATF1/CREB/ERK-SRF signaling
|
|
VasopressinR1 -> MEF/MYOD/NFATC/MYOG signaling
|
|
PTAFR -> NF-kB signaling
|
|
VasopressinR1 -> STAT signaling
|
|
CholecystokininR -> ELK-SRF signaling
|
|
AdenosineR -> NF-kB signaling
|
|
OxytocinR -> ELK-SRF/GATA/AP-1 signaling
|
|
NeurotensinR -> ELK-SRF/AP-1/EGR signaling
|
|
AdrenergicRa -> ELK-SRF signaling
|
|
AdenosineR -> AP-1 signaling
|
|
VasopressinR1 -> CREB/ELK-SRF/AP-1/EGR signaling
|
|
ProstaglandinFR -> ATF1/ELK-SRF/CREB signaling
|
|
OpioidR -> CREB/ELK-SRF/STAT3 signaling
|
|
GNRHR -> ELK-SRF signaling
|
|
GRM1/5 -> CREB signaling
|
|
AdrenergicRa -> STAT3 signaling
|
|
IL8R -> CREB/EGR signaling
|
|
EDG3/5 -> AP-1/ELK-SRF signaling
|
|
EndothelinRb -> AP-1/CREB/ELK-SRF signaling
|
|
ProstaglandinIR -> ATF1/ELK-SRF/CREB signaling
|
|
AdrenergicRb -> CREB signaling
|
|
TachykininR -> ELK-SRF signaling
|
|
VIPR -> CREB/CEBP signaling
|
|
EndothelinRa -> AP-1/CREB signaling
|
|
AdrenergicRb -> STAT3 signaling
|
|
AngiotensinR -> CREB/ELK-SRF/TP53 signaling
|
|
FSHR -> CREB/ELK-SRF/GATA4 signaling
|
|
VasopressinR2 -> CREB/ELK-SRF/AP-1/EGR signaling
|
|
VasopressinR2 -> MEF/MYOD/NFATC/MYOG signaling
|
|
ThromboxaneR -> CREB signaling
|
|
ThrombinR -> AP-1/CREB/ELK-SRF/SP1 signaling
|
|
B Cell Activation
|
|
Melanogenesis
|
|
Skeletal Myogenesis Control
|
|
Mast Cell Activation
|
|
Gonadotrope Cell Activation
|
|
Cell Cycle Regulation
|
|
T Cell Activation
|
|
NK Cell Activation
|
|
Gap Junction Regulation
|
|
Atlas of Signaling
|
|
Cyclosporine-Induced Nephrotoxicity
|
|
Doxorubicin-Induced Cardiotoxicity
|
|
Cytosolic Calcium Overload
|
|
Clozapine-Induced Granulocytopenia
|
|
ROS and RNS in the Regulation of Vasoconstriction and Vasodilation
|
|
ROS in Angiotensin-Mediated Cardiovascular Remodeling and Hypertrophy
|
|
ROS in Triggering Vascular Inflammation
|
|
ROS in Neutrophil-Mediated Cell Damage
|
|
NGF/FOXO/MYCN/ELK-SRF Expression Targets
|
|
BDNF Expression Targets
|
|
NTF3 Expression Targets
|
|
NTF4 Expression Targets
|
|
NGF/AP-1/TP53/MYC Expression Targets
|
|
NGF/CREB/CEBPB/MEF2A Expression Targets
|
|
NGF/SMAD3/NF-kB Expression Targets
|
|
ICAM1 Expression Targets
|
|
CD21 Expression Targets
|
|
Gamma Globulins Expression Targets
|
|
CD247 Expression Targets
|
|
FCGR3A Expression Targets
|
|
PLAU/ELK-SRF/AP-1 Expression Targets
|
|
CD19 Expression Targets
|
|
CD81 Expression Targets
|
|
Erythropoietin/ELK-SRF Expression Targets
|
|
NPY Expression Targets
|
|
Dopamine/Gi Expression Targets
|
|
Dronabinol/Anandamide Expression Targets
|
|
GNRH2 Expression Targets
|
|
Acetylcholine Expression Targets
|
|
PTPRC/BCL6 Expression Targets
|
|
AREG/SMAD1 Expression Target
|
|
AREG/AP-1 Expression Targets
|
|
AREG/HIF1A Expression Targets
|
|
AREG/NFATC Expression Target
|
|
BTC/EP300/ETS/ETV/SP1 Expression Targets
|
|
BTC/NFATC Expression Targets
|
|
EGF/HIF1A Expression Targets
|
|
EGF/TP53 Expression Targets
|
|
EREG/AP-1/ATF Expression Targets
|
|
EREG/EP300/SP1 Expression Targets
|
|
EREG/HIF1A Expression Target
|
|
HBEGF/AP-1/ATF Expression Targets
|
|
HBEGF/EP300/ETS/ETV/SP1 Expression Targets
|
|
HBEGF/HIF1A Expression Targets
|
|
HBEGF/MEF/MYOD Expression Target
|
|
HBEGF/TP53 Expression Targets
|
|
NRG1/AP-1/ATF Expression Targets
|
|
NRG1/EP300/ETS/ETV/SP1 Expression Targets
|
|
NRG1/HIF1A Expression Target
|
|
NRG1/MEF/MYOD Expression Targets
|
|
NRG1/TP53 Expression Target
|
|
TGFA/HIF1A Expression Targets
|
|
TGFA/MEF/MYOD/NFATC Expression Targets
|
|
TGFA/TP53 Expression Targets
|
|
FGF2/RUNX Expression Targets
|
|
FGF7/RUNX Expression Targets
|
|
FGF8/RUNX Expression Targets
|
|
FGF9/RUNX Expression Targets
|
|
VEGFA/NFATC Expression Targets
|
|
VEGFA/ATF/CREB/ELK-SRF Expression Targets
|
|
VEGFC/ATF Expression Target
|
|
GDNF/HSF1 Expression Targets
|
|
CTGF/AP-1/CREB/MYC Expression Targets
|
|
CTGF/NCOR2 Expression Target
|
|
Erythropoietin/AP-1/MYC/CREB Expression Targets
|
|
FLT3LG/AP-1/CREB/CREBBP Expression Targets
|
|
GAS6/AP-1/CREB Expression Targets
|
|
PGF/AP-1/CREB/CREBBP/MYC Expression Targets
|
|
Thrombopoietin/AP-1/CREB/CREBBP/MYC Expression Targets
|
|
AREG/CREB/CREBBP Expression Targets
|
|
AREG/NCOR2 Expression Targets
|
|
EGF/NCOR2 Expression Target
|
|
EREG/CREB Expression Target
|
|
HBEGF/CREB/MYC Expression Targets
|
|
NRG1/CREB/CREBBP/ELK-SRF/MYC Expression Targets
|
|
TGFA/CREB/CREBBP/ELK-SRF/MYC Expression Targets
|
|
FGF1/AP-1/CREB/ELK-SRF/MYC Expression Targets
|
|
FGF1/NCOR2 Expression Target
|
|
FGF2/NCOR2 Expression Targets
|
|
FGF4/AP-1/MYC Expression Targets
|
|
FGF7/AP-1/CREB/CREBBP/MYC Expression Targets
|
|
FGF8/AP-1/CREB/MYC Expression Targets
|
|
FGF9/AP-1/CREB/MYC Expression Targets
|
|
FGF10/AP-1/CREB/CREBBP/MYC Expression Targets
|
|
FGF18/AP-1/CREB Expression Targets
|
|
FGF23/NCOR2 Expression Targets
|
|
CSF1/AP-1/CREB/CREBBP/MYC Expression Targets
|
|
PDGFB/AP-1/CREB/MYC Expression Target
|
|
PDGFC/CREB Expression Target
|
|
PDGFD/AP-1 Expression Targets
|
|
VEGFA/NCOR2 Expression Target
|
|
ANGPT1/CREB/CREBBP Expression Targets
|
|
ANGPT2/AP-1/CREBBP/MYC Expression Targets
|
|
FIGF/AP-1 Expression Target
|
|
FIGF/NCOR2 Expression Target
|
|
F2 -> AP-1/CREB/ELK-SRF/SP1 Expression Targets
|
|
Thromboxane A2 Expression Targets
|
|
PLG -> AP-1/CREB/ELK-SRF/SP1 Expression Targets
|
|
OXT Expression Targets
|
|
Epinephrine/Gq Expression Targets
|
|
Adenosine Expression Targets
|
|
Prostaglandin F Expression Targets
|
|
Glutamate/Gq Expression Targets
|
|
AVP/Gq -> STAT Expression Targets
|
|
CCK Expression Targets
|
|
AVP/Gq -> MEF/MYOD/NFATC/MYOG Expression Targets
|
|
AVP/Gq -> CREB/ELK-SRF/AP-1/EGR Expression Targets
|
|
GNRH1 Expression Targets
|
|
Morphine Expression Targets
|
|
PAF/Gq -> NF-kB Expression Targets
|
|
NTS Expression Targets
|
|
GAST Expression Targets
|
|
S1P Expression Targets
|
|
TAC1 Expression Targets
|
|
PGE1 Expression Targets
|
|
Epinephrine/Gs Expression Targets
|
|
Noradrenaline/Gs Expression Targets
|
|
VIP Expression Targets
|
|
FSHR Expression Targets
|
|
AVP/Gs -> MEF/MYOD/NFATC/MYOG Expression Targets
|
|
AVP/Gs -> CREB/ELK-SRF/AP-1/EGR Expression Targets
|
|
Noreadrenaline/Gq Expression Targets
|
|
POMC Expression Targets
|
|
IFNA1/Gq Expression Targets
|
|
CXCL1 Expression Targets
|
|
CXCL2 Expression Targets
|
|
CXCL3 Expression Targets
|
|
CXCL5 Expression Targets
|
|
CXCL6 Expression Targets
|
|
EDN1 Expression Targets
|
|
EDN3 Expression Targets
|
|
ADCYAP1 Expression Targets
|
|
IL16/NF-kB Expression Targets
|
|
IL16/AP-1 Expression Targets
|
|
IL16/ATF/CREB/CREBBP Expression Target
|
|
CD8/NF-kB Expression Targets
|
|
CD8/AP-1 Expression Targets
|
|
CD8/ATF/CREB/CREBBP Expression Targets
|
|
CD80/NF-kB Expression Targets
|
|
CD80/AP-1 Expression Targets
|
|
CD80/ATF/CREB/CREBBP Expression Targets
|
|
CD86/NF-kB Expression Targets
|
|
CD86/AP-1 Expression Targets
|
|
CD86/ATF/CREB/CREBBP Expression Targets
|
|
CD22/NF-kB Expression Targets
|
|
CD72/NF-kB Expression Targets
|
|
CD72/AP-1 Expression Targets
|
|
CD72/CREB/CREBBP Expression Targets
|
|
PDCD1/NF-kB Expression Targets
|
|
PDCD1/AP-1 Expression Targets
|
|
PDCD1/ATF/CREB/CREBBP Expression Targets
|
|
TCR/AP-1 Expression Targets
|
|
TCR/CREB/CREBBP/ATF Expression Targets
|
|
AGT/TP53 Expression Targets
|
|
AGT/ELK-SRF Expression Targets
|
|
FGF2/AP-1/CREB/CREBBP/ELK-SRF/MYC Expression Targets
|
|
TCR/NF-kB Expression Targets
|
|
IL1B/PGE2 Expression Targets
|
|
AGT/CREB Expression Targets
|
|
EGF/AP-1/ATF Expression Targets
|
|
EGF/CREB/CREBBP/ELK-SRF/MYC Expression Targets
|
|
EGF/MEF/MYOD/NFATC Expression Targets
|
|
HGF/AP-1/CREB/ELK-SRF/MYC Expression Targets
|
|
KITLG/AP-1/CREB/CREBBP/MYC Expression Targets
|
|
LPA Expression Targets
|
|
PAF/Gq -> AP-1/ATF1/CREB/ERK-SRF Expression Targets
|
|
PDGF/AP-1/CREB/CREBBP/MYC Expression Targets
|
|
TCR/NFAT Expression Targets
|
|
TGFA/AP-1/ATF Expression Targets
|
|
VEGFA/AP-1/CREBBP/MYC Expression Targets
|
|
BTC/AP-1/ATF/CREB Expression Targets
|
|
FGF1/RUNX Expression Targets
|
|
dopamine signaling pathway
|
|
angiotensin II signaling pathway via AT1 receptor
|
|
kinin signaling pathway
|
|
protein kinase C (PKC) signaling pathway
|
|
acetylcholine signaling pathway via muscarinic acetylcholine receptor
|
|
dopamine signaling pathway
|